INNOventure

DigitalFirst.AI operates a business-to-business software-as-a-service platform designed to enhance online brand marketing and product sales for companies. The platform functions as a personal growth assistant, delivering personalized marketing strategies within minutes by utilizing generative AI. Users can validate their products and select effective marketing tactics simply by answering a few questions. Additionally, DigitalFirst.AI recommends a list of marketing activities based on insights from popular brands and experienced marketers. This approach enables companies to scale their revenues and enhance profits through improved customer acquisition.

We are a B2B Marketplace offering full support in printing services for companies around Europe. We deliver high quality print products containing all available print technologies on the market plus creative and product design, print process management with quality staging and logistic for the best Customer Success. We are all-in-one solution for any company, delivering time and cost savings, keeping the high quality production. It's simple, professional, it's easy... just prints me!

Minte.ai is a B2B medtech and insurtech company specializing in the automation of medical claims processing. Its software transforms unstructured medical documentation into structured information that can be easily processed by algorithms and understood by users. The company recently implemented its solution with Uniqa in Poland and is focused on expanding within the Polish market while aiming for break-even by 2025 and future growth in other EU countries. Minte.ai's technology significantly enhances efficiency, enabling insurance companies to save approximately 19,000 man-days per year for an average insurance product with 500,000 claims. This not only accelerates claims processing but also improves transparency, reduces customer churn, and aids in fraud detection and product enhancement. In the long term, Minte.ai plans to explore applications of its technology in other sectors requiring mass medical documentation processing, leveraging its deep tech expertise and proprietary intellectual property.

SKY ENGINE AI is a synthetic data cloud generative AI platform for data scientists enabling ai computer vision at scale software allows creating a digital twin of your sensor, drone, or robot and putting them through testing and training in a virtual environment prior to real-world deployment. They are data generation makes data scientist life easier providing perfectly balanced datasets for any computer vision applications like object detection and recognition. They include 3d positioning, pose estimation, and other sophisticated cases including analysis of multi-sensor data radars, lidars, satellites, x-rays, and more.

Cardiomatics specializes in cloud-based artificial intelligence software for the analysis of electrocardiogram (ECG) data. The company has developed a medical-grade system that employs proprietary algorithms validated against arrhythmia databases and clinical data. This technology ensures high-quality and reliable outcomes for healthcare providers. Cardiomatics collaborates with physicians, manufacturers, and ECG device providers worldwide, facilitating the delivery of clear and concise reports that enhance diagnostic accuracy and streamline clinical workflows.

ARAHUB - integrated system for behavioral targeting advertisement in digital outdoor, which enable the analysis of recipient: gender, age, interests and shopping intentions, and is able to assess their response to a message.

SGPR.TECH Sp. z o.o. specializes in developing analytical software and innovative ground penetrating radar technology for subsurface surveying. Founded in 2018 and located in Rzeszów, Poland, the company provides solutions for various industries, including mining, oil and gas, and construction. Their software enables accurate subsurface mapping and material recognition, facilitating the creation of detailed 3D models that contain comprehensive subsurface information. By offering advanced tools for multispectral subsurface modeling, SGPR.TECH aims to transform how industries reliant on subsurface data gather and analyze information, thereby enhancing project efficiency and addressing challenges at every stage of development.

SDS Optic, based in Lublin, is an innovative biotech company that develops advanced diagnostic solutions aimed at improving cancer detection and treatment. The company operates at the intersection of biochemistry, engineering, and fiber optic technologies, creating methodologies for in-vivo cancer diagnosis with single-cell resolution. SDS Optic specializes in the pre-assembly of both hermetic and standard photoelectronics components, contributing to the efficiency and effectiveness of its diagnostic tools. By focusing on novel approaches in oncology, the company addresses the pressing needs of patients and healthcare providers, striving for quicker and less painful diagnostic processes.

SiDLY is a rapidly growing company specializing in telemedicine through its innovative AI medical technology. The firm offers a comprehensive platform that combines eHealth and eCare, enabling individuals to access medical diagnostics and conduct ongoing health monitoring remotely. Its flagship product, the SiDLY medical wristband, works in conjunction with an AI-based telemedicine system and a mobile application, facilitating effective medical services while reducing reliance on institutional care. With a repository of over 380 million qualitative medical data points, SiDLY is positioned to create valuable AI-driven health services. In recognition of its growth and impact in the sector, the company was named the fastest-scaling technology firm in 2023 by Deloitte's CE Technology Fast 50.

PolTREG is a biotechnology company focused on developing innovative therapies using T-regulatory cells (TREGs) for the treatment of autoimmune diseases, notably type 1 diabetes and multiple sclerosis. Established as a spin-off from the Medical University of Gdańsk, the company aims to commercialize its patented TREG method, which has shown promising results in clinical trials. PolTREG's portfolio includes four advanced projects currently in clinical development, backed by a team of experienced managers, biotechnology specialists, and scientists. The founders bring over 17 years of expertise in T-regulatory cell applications for autoimmune therapies. The company's Scientific Advisory Board comprises leading experts in the field, ensuring a strong foundation for research and development. PolTREG is uniquely positioned as the sole entity authorized to implement its research findings and utilize its growth method for clinical applications, with a commitment to delivering its breakthrough therapies to patients.